Global Amyloid Proteins Market Insights
The global amyloid proteins market is estimated to grow at a significant CAGR during the forecast period. The Amyloid Proteins market is majorly driven due to increased incidence of Alzheimer’s among the population across the globe. However, according to the experts and growing evidence, earlier oligomer stages of beta amyloid are most likely to be toxic to the brain cells. High toxicity is among the major factors expected to hamper the growth of amyloid proteins market over the forecast period. Increased usage of amyloid proteins by the biotechnology and lifesciences company is expected to propel the growth of amyloid proteins market. Amyloids are the aggregates of proteins which are folded into a shape that allows multiple copies of protein to stick together, thereby forming fibrils. In human body the amyloid has been linked to the development of various diseases. Growing use of amyloidosis in the treatment of neurodegenerative disorders is expected to spur the growth of amyloid proteins market over the forecast period. However, presence of infectious amyloid proteins such as prions is expected to be one of the major hurdles in the growth of market.
Amyloid Proteins Market: By Application
The global amyloid proteins market can be segmented on the basis of application into immunohistochemistry, and western blotting among others. The immunohistochemistry (IHC) is the common application of immunostaining. IHC involves the process of selectively identifying proteins in the cells of a tissue section through exploiting the principle of antibodies binding specifically to antigens in biological tissues. Increased diagnosis of abnormal cells such as the cells found in cancerous tumors is one of the major factors expected to drive the growth of segment. Increased use of immunohistochemistry in the basic research in order to identify the distribution and localization of biomarkers is expected to propel the growth of segment.
Amyloid Proteins Market: By Reactivity
The amyloid proteins market is segmented on the basis of reactivity into human, mouse, rat, horse, bovine, canine, and pig among others. Increased T cell reactivity to amyloid beta protein in older patients and humans suffering with Alzheimer’s disease is expected to drive the growth of human segment.
Amyloid Proteins Market: By Structure Identification method
The market for amyloid proteins is segmented on the basis of By Structure Identification method into solid state NMR spectroscopy, and electron microscopy. Solid state NMR spectroscopy method possesses unique capability to provide detailed structural constraints for the amyloid fibrils. Whereas, the transmission electron microscopy of cyro prepared and negatively stained specimens allow amyloid fibrils to be visualized at high resolution in a hydrated or dry state. The electron microscopy is an essential method for characterizing the morphology of pre-fibrillar and fibrils species.
Amyloid Proteins Market: By Component
The market for amyloid proteins is segmented on the basis of component into amyloid beta peptides, alpha-synuclein, tau, and FUS protein among others. Growing incidence of Alzheimer’s disease is expected to drive the market of amyloid beta peptides. Alzheimer’s disease is majorly believed to be driven by the production and decomposition of the beta amyloid peptide. Various reliable evidence indicates that the solubility property of beta amyloid peptides, and the quantity of beta amyloid peptide in different pools is more closely related to the disease state.
Amyloid Proteins Market: By End Use
The market for amyloid proteins is segmented on the basis of end use industry vertical into pharmaceutical, biotechnology, and research & laboratory among others. The biotechnology segment is expected to generate highest CAGR over the forecast period. The growth of the segment can be attributed to the increased demand for amyloid beta peptides for various cell culture and cell biology applications. Growing demand for amyloid fibrils for immunohistochemistry, and western blotting among other applications is expected to spur the growth of biotechnology and lifesciences segment.
Amyloid Proteins Market: Regional Insights
On the basis of region the market for amyloid proteins is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America. North America is expected to dominate the market of Amyloid Proteins. The market in the region is majorly driven due to increased incidence of various diseases such as Alzheimer’s, Parkinson’s, and Fatal familial insomnia among others. Moreover presence of major manufacturers in the region is also expected to drive the growth of market in the region. Other factors such as increasing incidence of lung cancer coupled with increased death due to lung cancer are expected to propel the growth of market in the region. Whereas, the Asia Pacific market is expected to grow at a highest CAGR during the forecast period, the region’s growth can be attributed to the growing biotechnology and lifesciences Company in the region.
Amyloid Proteins Market: Vendor Landscape
The report contains a chapter dedicated to vendors operating in the market, covering raw material manufactures, equipment developers, manufacturers, and distributors. The report provides these insights on a regional level. This section of the report entails contact details, experience, Systems manufactured/supplied, and geographical presence of companies.
Amyloid Proteins Market: End-Use Landscape
The end-use landscape entails a list of current and prospective consumers prevailing across the regions. This section provides company addresses, contact details, Systems, and regional presence of companies who are purchasing or are likely to purchase Amyloid Proteins in the coming years. Some companies’ currently using Amyloid Proteins and are likely to purchase it in future are Mayo Clinic, Johns Hopkins Hospital, and Mount Sinai Hospitals among others.
Amyloid Proteins: Market Share & Competitor Analysis
Some of the key players operating in the amyloid proteins market include Sigma Aldrich, Merck Millipore, Pfizer, Novartis, Roche, Merck & Co., AbbVie, Amgen, Abbott Laboratories, Eli Lilly & Co, Sanofi, and AstraZeneca among others.
In February 2019, Alector, a company taking an immunotherapy approach to Alzheimer’s disease and other brain disorders, has raised approximately $176 million in an initial public offering. Alector is developing AL002 and AL003 in an alliance with AbbVie
In May 2019, Pfizer announced that US FDA (Food and Drug Administration) has approved VYNDAMAX (tafamidis) and VYNDAQEL (tafamidis meglumine) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Avail customized purchase options to meet your exact research needs: